Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia

BACKGROUND: Levodopa‐induced dyskinesias are an often debilitating side effect of levodopa therapy in Parkinson's disease. Although up to 90% of individuals with PD develop this side effect, uniformly effective and well‐tolerated antidyskinetic treatment remains a significant unmet need. The pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Steece‐Collier, Kathy, Stancati, Jennifer A., Collier, Nicholas J., Sandoval, Ivette M., Mercado, Natosha M., Sortwell, Caryl E., Collier, Timothy J., Manfredsson, Fredric P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563183/
https://www.ncbi.nlm.nih.gov/pubmed/31002755
http://dx.doi.org/10.1002/mds.27695

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563183/
https://www.ncbi.nlm.nih.gov/pubmed/31002755
http://dx.doi.org/10.1002/mds.27695

Ejemplares similares